A Phase 3 interventional study of Donanemab and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 216 sites in 3 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.
Among the 15 studies testing donanemab in Alzheimer Disease, this one has the largest planned enrollment, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 6th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:
Banner Health · Sites in Colombia
Ages 25–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in China
Ages 55–80
Paul S. Aisen · Sites in United States
Ages 50–80
By country, each count listing its studies:
donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2013; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 2,996 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 240 across the 15 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 2nd largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2021, is one of 24 in phase 3, reaches primary completion later than 6 of the 18 other live ones, and was the 79th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
1 of the studies testing donanemab in Alzheimer Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing donanemab in Alzheimer Disease, from their registry updates:
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment Extension: (Study Period II Placebo Group Only)
Exclusion Criteria:
Addendum 7 Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donanemab administered intravenously (IV)
Drug: Donanemab
Placebo is administered intravenously
Drug: Placebo
Administered intravenously
Also known as: LY3002813
Administered intravenously
Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])
Time to clinical progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage on the spectrum of Alzheimer's Disease (AD) dementia
Time frame: Estimated up to Week 332
Change from Baseline in Cognitive Composite in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in Cognitive Composite in the Primary Study Population (CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in International Shopping List Test (ISLT) in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by ISLT in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in Continuous Paired Associate Learning (CPAL ) in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by CPAL in the Primary Study Population (baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by iDSSTm in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in Category Fluency in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by Category Fluency in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in CDR-Sum of Boxes (CDR-SB) n the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by CDR-SB in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up Week 332
Change from Baseline in Cognitive Function Index (CFI) in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by CFI in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in Montreal Cognitive Assessment (MoCA) Score in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in clinical progression as measured by MoCA score in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C) in the Primary Study Population (Baseline CDR-GS 0)
Change from baseline in MBI-C in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Baseline, Up to Week 332
Time to Clinical Progression of Composite Endpoint as Measured by CDR in the Overall Study Population (Baseline CDR-GS 0 or 0.5)
Time to clinical progression as measured by CDR in the Overall Study Population (Baseline CDR-GS 0 or 0.5)
Time frame: Baseline, Up to Week 332
Time to Clinical Progression as Measured by CDR Memory Box in Primary Study Population (Baseline CDR-GS 0)
Time to clinical progression as measured by CDR Memory Box in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Estimated up to Week 332
Time to Clinical Progression as Measured by CDR Judgment and Problem Solving Box in the Primary Study Population (Baseline CDR-GS 0)
Time to clinical progression as measured by CDR Judgment and Problem Solving Box in the Primary Study Population (Baseline CDR-GS 0)
Time frame: Estimated up to Week 332
Time to Clinical Progression as Measured by At Least 0.5 Change on CDR-SB in Primary Study Population (Baseline CDR-GS 0)
Time to clinical progression as measured by at least 0.5 change on CDR-SB in Primary Study Population (Baseline CDR-GS 0)
Time frame: Estimated up to Week 332
Time to Clinical Progression of Composite Endpoint as Measured by CDR in Subpopulation Positive Based on Secondary Diagnostic Test
Time to clinical progression as measured by CDR in subpopulation positive based on secondary diagnostic test
Time frame: Estimated up to Week 332
Change from Baseline in Plasma P-tau217
Change from baseline in Plasma P-tau217
Time frame: Baseline, Up to Week 332
Pharmacokinetics (PK): Average Serum Donanemab Concentration at Steady State
PK: Average serum donanemab concentration at steady state
Time frame: Baseline through Week 76
Percentage of Participants with Treatment-emergent Anti-Drug Antibody (ADAs)
Percentage of participants with treatment-emergent anti-drug antibody (ADAs)
Time frame: Baseline through Week 16
Showing the first 100 of 216 sites across 3 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Aug 2021 (actual). Primary completion is estimated for Nov 2027, 75 months after the start.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 75 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donanemab